GlassScriptPhysician profile
Brian R Bodnarchuk
NPI 1760825624
$6,426.23
in general payments reported to CMS, 2019-2025
32 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $305 · 2021: $593 · 2022: $1,029 · 2023: $1,259 · 2024: $1,687 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,130.18 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $805.02 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Regeneron Healthcare Solutions, INC. | $603.91 | 2019-2025 | Eylea, Eylea Hd |
| Genentech USA, INC. | $532.84 | 2019-2025 | Vabysmo |
| Allergan, INC. | $431.71 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $275.00 | 2022-2025 | Syfovre |
| Oyster Point Pharma, INC. | $272.46 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $260.47 | 2019-2021 | |
| Biogen, INC. | $233.49 | 2022-2023 | |
| Rxsight INC | $204.40 | 2022-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $186.08 | 2023-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $182.60 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $171.35 | 2019-2023 | |
| Ocular Therapeutix, INC. | $159.65 | 2023-2024 | Dextenza |
| Bausch & Lomb Americas INC. | $131.49 | 2022-2025 | Xiidra, Envista Mx60 Iol, Miebo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $122.51 | 2022-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Aerie Pharmaceuticals, INC. | $121.11 | 2019-2021 | |
| Sight Sciences, INC. | $93.23 | 2023 | Omni Surgical System |
| Coopervision INC. | $86.50 | 2023 | Myday Contact Lens |
| Glaukos Corporation | $61.46 | 2022-2025 | Idosetr, Idose |
| Astellas Pharma US INC | $59.63 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $47.81 | 2024-2025 | Xdemvy |
| Alimera Sciences, INC. | $42.31 | 2023-2024 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $34.90 | 2023 | |
| Mallinckrodt Hospital Products INC. | $32.92 | 2023 | Acthar |
| Dompe US, INC. | $31.34 | 2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $29.40 | 2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Horizon Therapeutics Plc | $24.26 | 2022 | |
| Amgen INC. | $21.69 | 2025 | Tepezza |
| Shire North American Group INC | $15.59 | 2019 | |
| Quidel Corporation | $11.19 | 2020 | |
| Biotissue Holdings INC. | $9.73 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bodnarchuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.